# A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure

> **NCT07083011** · PHASE2 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 35 (estimated)

## Conditions studied

- Heart Failure With Preserved Ejection Fraction

## Interventions

- **DRUG:** 68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor)

## Key facts

- **NCT ID:** NCT07083011
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-01
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07083011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07083011, "A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07083011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*